Navigation Links
D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
Date:3/1/2011

PITTSBURGH, March 1, 2011 /PRNewswire/ -- D3 Oncology Solutions (D3), formerly D3 Radiation Oncology Solutions, has added Via Oncology Pathways for medical oncology to the company's suite of solutions. With this new offering, D3 now offers integrated pathways programs to both medical and radiation oncology practices across the globe. Via Oncology Pathways are evidence-based clinical algorithms that standardize best practice cancer treatment, optimize patient outcomes, minimize toxicities, and promote efficient resource utilization. These cancer care pathways have been developed and implemented across multiple practices by both academic and community based oncologists since 2005.

(Logo: http://photos.prnewswire.com/prnh/20110301/NE55044LOGO)

Currently, D3's Via Oncology Pathways cover more than 85 percent of cancer diagnoses and include chemotherapy and biologics, radiation therapy, prognostic testing and supportive care treatments. All aspects of the pathways are delivered through a web-based, patient-specific, point of care decision-support tool that integrates into the practice's other information technologies. Additionally, advance care planning support is seamlessly built into the software to support the physician's workflow.

"Oncologists have asked us to help them become optimally positioned to participate in many of the healthcare reform vehicles such as medical homes, accountable care organizations (ACOs) and demonstration projects. They want to be able to prove the value of their cancer program to patients, referring physicians and health plans by clearly demonstrating evidence-based, cost-effective care," said Kathleen Lokay, president, D3 Oncology Solutions. "D3's Via Oncology Pathways are a proven tool for measuring and proving the value of care delivered."

Every quarter, approximately 30 different disease-specific physician committees of academic and community-based physicians convene to review the Pathways based on their independent evaluation of the latest medical literature.

"It's no longer enough to simply say that you have quality. The practices that will be successful in the future are those that can demonstrate a system of quality and cost effectiveness and quantify those results on a repeatable basis. Via Oncology Pathways provide the tools to prove it," noted Peter Ellis, M.D., medical director for Via Oncology Pathways and a practicing medical oncologist at UPMC.

About D3 Oncology SolutionsThe mission of D3 Oncology Solutions is to develop and deliver leading edge solutions that accelerate the quality, safety, efficiency and outcomes of cancer patients' care at radiation and medical oncology centers around the world.

With unmatched expertise for more than a decade, D3 has assisted hundreds of cancer centers in the United States and internationally. D3's solutions are guided by close collaboration with leading radiation oncologists, medial oncologists and medical physicists at UPMC and UPMC Cancer Centers.

From flexible options for linear accelerator commissioning, clinical training and radiation treatment planning to tools and programs that support clinical quality such as Via Oncology Pathways, D3's suite of solutions accelerates excellence in the delivery of cancer care.  

D3 is an affiliate of UPMC, an integrated global health enterprise headquartered in Pittsburgh and one of the leading health systems in t he United States. For more information, visit www.d3onc.com or call (412) 365-0710. Media ContactsD3:Andrew Bailey(412) 365-0744 or baileya@d3onc.comEuro RSCG Worldwide PR:Ellen Wein(412) 456-0986 or ellen.wein@eurorscg.com
'/>"/>

SOURCE D3 Oncology Solutions
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
2. DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
3. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
4. TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch
5. Sentinel Oncology add ADME From O2h to Their New Extended Contract
6. US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials
7. US Oncology to Report 2010 Third Quarter Operating Results
8. Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
9. Dr. Ramin Mirhashemi, MD of Gynecological Oncology Associates Discusses Uterine Fibroid Treatment with da Vinci Robotic Hysterectomy Surgery
10. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
11. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... CT (PRWEB) , ... July 25, 2017 , ... ... products that enhance the microbiome and improve efficiency of livestock farming while reducing ... that it has licensed additional intellectual property from Cornell University. , These ...
(Date:7/24/2017)... ... July 24, 2017 , ... Each year, Inavero’s Best ... proven their superior service quality as rated by hiring professionals and job candidates. ... based on service quality ratings from their placed talent. , Fewer than 2% ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... leading radiology and imaging centers around the U.S. that offer MR Elastography for ... alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect was ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture ... the company’s board of directors. This addition continues to strengthen and diversify VIC’s ... Goforth, CEO and Chairman. “He is a highly accomplished business executive with a broad ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):